Metabolic & Weight Management
Retatrutide
Also known as LY3437943 · triple-G agonist
Emerging researchSubcutaneous injectionNot FDA-approved; investigational, in late-stage (Phase 3) clinical trials as of 2026.
Retatrutide is an investigational single molecule that acts as an agonist at three receptors: GIP, GLP-1, and glucagon. The added glucagon-receptor activity is thought to increase energy expenditure alongside the appetite and glycemic effects of the incretin pathways. It is in late-stage clinical development and is not yet approved.
Studied / used for
- studied for weight management in obesity/overweight
- studied for type 2 diabetes
- studied for metabolic dysfunction-associated steatotic liver disease (MASLD)
Commonly reported side effects
- nausea
- diarrhea
- vomiting
- constipation
- decreased appetite
Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.
Not medical advice.
This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.